Abbvie Biotherapeutics Inc.

Abbott Biotherapeutics Corp.

Protein Design Labs, Inc.

Pdl Biopharma, Inc.

Boehringer Mannheim Gmbh

Facet Biotech Corporation

Jn Biosciences LLC

Nicholas F Landolfi

J Yun Tso

Gao Liu

Marna Williams

Naoya Tsurushita

David Powers

Cary L Queen

Maximiliano Vasquez

Shankar Kumar

Paul Robert Hinton

Man Sung Co

Harold E Selick

Ulrich Martin

Chung Nan Chang

Kathleen L Coelingh

William P Schneider

Balaji Balasa

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.

Therapeutic use of anti-CS1 antibodies

The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications.

Antibodies to CD122

The present invention is directed to high affinity anti-human IP-10 antibodies or antigen-binding fragments of these antibodies, including chimeric, humanized or fully human antibodies. The present invention is also directed to a method of reducing the severity of at least one symptom of an inflammatory bowel disease in a subject in need thereof comprising administering to said subject an effective amount of an antagonist of IP-10, including the antibodies or antibody fragments of the present invention.

Treatment of inflammatory bowel diseases with anti-IP-10 antibodies

The present invention is directed to anti-AR antibodies, preferably humanized monoclonal antibodies having the amino acid sequences disclosed herein. The present invention includes a pharmaceutical composition comprising such antibodies. The present invention includes a method of inhibiting cancer cell growth comprising administering such antibodies into a subject. The present invention also provides a method of treating cancer or psoriasis in a subject in need of such a treatment by administering such antibodies to said subject in a pharmaceutically effective amount.

Amphiregulin antibodies and their use to treat cancer and psoriasis

The invention provides humanized immunoglobulins that bind to and neutralize &#x3b3;-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.

Humanized antibodies to gamma-interferon

Growing community of inventors

Menlo Park, CA, United States of America

Nicholas F Landolfi